Evidence-Based Medicine Guidelines
Intravenous heparin or low-molecular weight heparin in patients with acute myocardial infarction treated with thrombolytic therapy
Intravenous heparin or low-molecular weight heparin in patients with acute myocardial infarction treated with thrombolytic therapy is a topic covered in the Evidence-Based Medicine Guidelines.
To view the entire topic, please log in or purchase a subscription.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Intravenous Heparin or Low-molecular Weight Heparin in Patients With Acute Myocardial Infarction Treated With Thrombolytic Therapy." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/455882/all/Intravenous_heparin_or_low_molecular_weight_heparin_in_patients_with_acute_myocardial_infarction_treated_with_thrombolytic_therapy.
Intravenous heparin or low-molecular weight heparin in patients with acute myocardial infarction treated with thrombolytic therapy. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. https://evidence.unboundmedicine.com/evidence/view/EBMG/455882/all/Intravenous_heparin_or_low_molecular_weight_heparin_in_patients_with_acute_myocardial_infarction_treated_with_thrombolytic_therapy. Accessed August 14, 2022.
Intravenous heparin or low-molecular weight heparin in patients with acute myocardial infarction treated with thrombolytic therapy. (2019). In Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited. https://evidence.unboundmedicine.com/evidence/view/EBMG/455882/all/Intravenous_heparin_or_low_molecular_weight_heparin_in_patients_with_acute_myocardial_infarction_treated_with_thrombolytic_therapy
Intravenous Heparin or Low-molecular Weight Heparin in Patients With Acute Myocardial Infarction Treated With Thrombolytic Therapy [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. [cited 2022 August 14]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/455882/all/Intravenous_heparin_or_low_molecular_weight_heparin_in_patients_with_acute_myocardial_infarction_treated_with_thrombolytic_therapy.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Intravenous heparin or low-molecular weight heparin in patients with acute myocardial infarction treated with thrombolytic therapy
ID - 455882
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/455882/all/Intravenous_heparin_or_low_molecular_weight_heparin_in_patients_with_acute_myocardial_infarction_treated_with_thrombolytic_therapy
PB - Duodecim Medical Publications Limited
DB - Evidence Central
DP - Unbound Medicine
ER -
